Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Pharmacy Benefits Management Services

Menu
Menu

Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge
 

VA Center For Medication Safety (VA MedSAFE)

Drug Safety Features

LOOK-ALIKE/SOUND-ALIKE EFFORTS

Alerts

PBM WARNING LETTER: Sulfasalazine and Sulfadiazine LA/SA Errors

Warning Letter - Sulfasalazine-Sulfadiazine LA-SA Errors

Look-Alike Sound-Alike Confusion Potential with Humapen Memoir® and Humira® Pen – January 2007

Two Pens Different Uses; PBM Ez-Minutes January – March 2007
HUMIRA Pen and HumaPen; ISMP Newsletter April 2007


Look-Alike Sound-Alike Vaccine Mix-ups: Adacel (Tdap) and Daptacel (DTaP) – August 24, 2006

ISMP Newsletter


Fluarix® and Twinrix® Look-Alike Confusion Potential

National PBM Bulletin - Look-Alike Safety Alert Regarding Fluarix® and Twinrix®

LOOK-ALIKE SAFETY ALERT FOR HALOPERIDOL AND CYANOCOBALAMIN 1ML VIALS National PBM Bulletin 

Pilot Project for Determining Look-alike Sound-alike Drug Names for New Molecular Entities (NMEs)

LASA Draft Paper
Appendix I 
Appendix II 
Appendix III

VA-Specific LASA pairs

Cumulative VA LASA list 2016
 VA LASA list 2016

Institute for Safe Medication Practice

ISMP Confused Drug Name

FDA LASA Alerts for 2011 

 
PHARMACOVIGILANCE AND DRUG SAFETY PROJECTS
  1. GENERAL SAFETY PROJECTS/PILOT PROJECTS
    1. Adverse Drug Event (ADE) Reporting
    2. Look-Alike Sound-Alike (LA/SA) Drug Names for New Molecular Entities (NMEs)
    3. Active Surveillance – Signal Detection
  2. SITE-BASED MEDICATION SAFETY EVALUATIONS
    1. Conversion to and Initiation with Travoprost in Glaucoma Management
    2. Erythropoeitin Stimulating Agents (ESA) Database Medication Use Evaluation (MUE) Tracker
    3. Evaluation of Amiodarone Monitoring
  3. RISK REDUCTION PROJECTS
    1. Glyburide Use in Patients with Renal Insufficiency
    2. High Dose Zolpidem
    3. High Dose Atypical Antipsychotic
  4. DRUG SURVEILLANCE/PHARMACOVIGILANCE PROJECTS (Ongoing)
    1. Polypharmacy in Post Traumatic Stress Disorder (PTSD)
    2. Atypical Antipsychotic/SSRI/Benzodiazepine Rapid Cycle Analysis
    3. Varenicline Rapid Cycle Analysis
    4. PPIs Rapid Cycle Analysis
    5. Rapid Cycle Evaluation of Thiazolidinediones
    6. Long-Acting Opioids
    7. Bisphosphonates Pharmacovigilance-Rapid Analysis
    8. Rapid Cycle Analysis: Bevicizumab and Ranibizumab
    9. Rapid Cycle Signal Strengthening Evaluation: PPIs, H2Bs, and ACEs
    10. Rapid Cycle Analysis - Antiviral Drugs: Amantadine, Oseltamivir, Rimantadine, and Zanamivir
    11. Osteoporosis
    12. Vaccine Safety
    13. Influenza Project
    14. Risperidone
    15. Varenicline
    16. Beta-Blockers
    17. Glyburide
    18. Warfarin
    19. Fluoroquinolones